Search details
1.
Methodological considerations for observational studies of treatment effectiveness in neurology: a clinician's guide.
J Neurol Neurosurg Psychiatry
; 95(5): 454-460, 2024 Apr 12.
Article
in English
| MEDLINE | ID: mdl-37890986
2.
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 2024 Mar 27.
Article
in English
| MEDLINE | ID: mdl-38538060
3.
Rates of John Cunningham virus seroconversion greatly reduced in natalizumab-treated patients during COVID-19-related lockdowns.
Eur J Neurol
; 31(1): e16059, 2024 01.
Article
in English
| MEDLINE | ID: mdl-37707348
4.
Observational studies of treatment effectiveness in neurology.
Brain
; 146(12): 4799-4808, 2023 12 01.
Article
in English
| MEDLINE | ID: mdl-37587541
5.
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Brain
; 146(11): 4633-4644, 2023 11 02.
Article
in English
| MEDLINE | ID: mdl-37369086
6.
Risk of secondary progressive multiple sclerosis after early worsening of disability.
J Neurol Neurosurg Psychiatry
; 94(12): 984-991, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37414538
7.
Disability accrual in primary and secondary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(9): 707-717, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37068931
8.
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
J Neurol Neurosurg Psychiatry
; 94(12): 1004-1011, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37414534
9.
Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis.
Mult Scler
; 29(6): 657-667, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36802988
10.
External validation of a clinical prediction model in multiple sclerosis.
Mult Scler
; 29(2): 261-269, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36448727
11.
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Mult Scler
; 29(3): 326-332, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36800908
12.
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.
Eur J Neurol
; 30(4): 1014-1024, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36692895
13.
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry.
J Neurol Neurosurg Psychiatry
; 2022 Sep 30.
Article
in English
| MEDLINE | ID: mdl-36180218
14.
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
Mult Scler
; 28(11): 1752-1761, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35373638
15.
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Eur J Neurol
; 29(8): 2321-2334, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35582938
16.
Trajectories of Mini-Mental State Examination Scores over the Lifespan in General Populations: A Systematic Review and Meta-Regression Analysis.
Clin Gerontol
; 45(3): 467-476, 2022.
Article
in English
| MEDLINE | ID: mdl-32374211
17.
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
Mult Scler
; 27(5): 755-766, 2021 04.
Article
in English
| MEDLINE | ID: mdl-32538713
18.
Early clinical markers of aggressive multiple sclerosis.
Brain
; 143(5): 1400-1413, 2020 05 01.
Article
in English
| MEDLINE | ID: mdl-32386427
19.
Predicting all-cause unplanned readmission within 30 days of discharge using electronic medical record data: A multi-centre study.
Int J Clin Pract
; 75(8): e14306, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-33960566
20.
The histopathological staging of tau, but not amyloid, corresponds to antemortem cognitive status, dementia stage, functional abilities and neuropsychiatric symptoms.
Int J Neurosci
; 131(8): 800-809, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-32303140